NCT05429073View on ClinicalTrials.gov

A Study of RGLS8429 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

September 8, 2022

Study Completion Date

September 8, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

RGLS8429

solution for subcutaneous injection

DRUG

Placebo volume-matching RGLS8429 dose

solution for subcutaneous injection

Trial Locations (1)

78209

ICON Early Phase Services, San Antonio

All Listed Sponsors

lead

Regulus Therapeutics Inc.

INDUSTRY